Immunic to Participate in Investor and Scientific Conferences in September
Immunic (NASDAQ: IMUX), a biotechnology company focused on inflammatory and autoimmune diseases, has announced its participation in three major conferences in September 2025. The company will present at the H.C. Wainwright Global Investment Conference (Sept 8-10), attend the Leerink Partners Biopharma Summit (Sept 17-19), and participate in the 41st ECTRIMS Congress (Sept 24-26).
At ECTRIMS, the company will showcase significant data on its lead drug candidate vidofludimus calcium (IMU-838), featuring one oral presentation and four poster presentations. The presentations will focus on the drug's efficacy and safety in multiple sclerosis treatment, including results from the Phase 2 CALLIPER trial in progressive MS and long-term safety data from the EMPhASIS trial in relapsing-remitting MS.
Immunic (NASDAQ: IMUX), società biotecnologica focalizzata su malattie infiammatorie e autoimmuni, ha comunicato la sua partecipazione a tre importanti conferenze di settembre 2025. L'azienda presenterà al H.C. Wainwright Global Investment Conference (8-10 settembre), parteciperà al Leerink Partners Biopharma Summit (17-19 settembre) e prenderà parte al 41st ECTRIMS Congress (24-26 settembre).
All'ECTRIMS la società presenterà dati rilevanti sul suo candidato principale, il vidofludimus calcium (IMU-838), con una presentazione orale e quattro poster. Le esposizioni verteranno sull'efficacia e la sicurezza del farmaco nel trattamento della sclerosi multipla, includendo i risultati dello studio di Fase 2 CALLIPER sulla SM progressiva e i dati di sicurezza a lungo termine dallo studio EMPhASIS sulla SM recidivante-remittente.
Immunic (NASDAQ: IMUX), una compañía biotecnológica centrada en enfermedades inflamatorias y autoinmunes, ha anunciado su participación en tres conferencias importantes en septiembre de 2025. La empresa presentará en la H.C. Wainwright Global Investment Conference (8-10 de septiembre), asistirá al Leerink Partners Biopharma Summit (17-19 de septiembre) y participará en el 41st ECTRIMS Congress (24-26 de septiembre).
En ECTRIMS la compañía mostrará datos significativos sobre su candidato principal, el vidofludimus calcium (IMU-838), con una presentación oral y cuatro pósteres. Las presentaciones se centrarán en la eficacia y seguridad del fármaco en el tratamiento de la esclerosis múltiple, incluyendo los resultados del ensayo de Fase 2 CALLIPER en esclerosis múltiple progresiva y los datos de seguridad a largo plazo del ensayo EMPhASIS en esclerosis múltiple remitente-recurrente.
Immunic (NASDAQ: IMUX), 염증 및 자가면역 질환에 주력하는 생명공학 기업이 2025년 9월에 열리는 주요 학회 세 곳에 참여한다고 발표했습니다. 회사는 H.C. Wainwright Global Investment Conference에(9월 8-10일) 발표를 하고, Leerink Partners Biopharma Summit(9월 17-19일)에 참석하며, 41st ECTRIMS Congress(9월 24-26일)에 참가할 예정입니다.
ECTRIMS에서는 주력 후보 약물인 vidofludimus calcium (IMU-838)에 대한 중요한 데이터를 공개하며, 구두 발표 1건과 포스터 발표 4건을 선보입니다. 발표들은 진행성 다발성 경화증에 대한 CALLIPER 2상 시험 결과와 재발완화형 다발성 경화증의 EMPhASIS 시험에서 얻은 장기 안전성 데이터를 포함해 이 약물의 효과성과 안전성에 초점을 맞춥니다.
Immunic (NASDAQ: IMUX), une société biotechnologique spécialisée dans les maladies inflammatoires et auto-immunes, a annoncé sa participation à trois conférences majeures en septembre 2025. La société présentera à la H.C. Wainwright Global Investment Conference (8-10 sept.), assistera au Leerink Partners Biopharma Summit (17-19 sept.) et participera au 41st ECTRIMS Congress (24-26 sept.).
Lors de l'ECTRIMS, la société dévoilera des données importantes sur son principal candidat-médicament, le vidofludimus calcium (IMU-838), avec une présentation orale et quatre posters. Les interventions porteront sur l'efficacité et la sécurité du médicament dans le traitement de la sclérose en plaques, incluant les résultats de l'essai de phase 2 CALLIPER dans la SEP progressive et les données de sécurité à long terme de l'essai EMPhASIS dans la SEP récurrente-rémittente.
Immunic (NASDAQ: IMUX), ein Biotechnologieunternehmen mit Schwerpunkt auf entzündlichen und Autoimmunerkrankungen, hat seine Teilnahme an drei wichtigen Konferenzen im September 2025 angekündigt. Das Unternehmen wird auf der H.C. Wainwright Global Investment Conference (8.–10. Sept.), beim Leerink Partners Biopharma Summit (17.–19. Sept.) und beim 41st ECTRIMS Congress (24.–26. Sept.) vertreten sein.
Auf dem ECTRIMS wird das Unternehmen bedeutende Daten zu seinem führenden Wirkstoffkandidaten, dem vidofludimus calcium (IMU-838), vorstellen – darunter eine mündliche Präsentation und vier Poster. Die Beiträge konzentrieren sich auf Wirksamkeit und Sicherheit des Medikaments bei der Behandlung der Multiplen Sklerose, einschließlich der Ergebnisse der Phase-2-Studie CALLIPER bei progredienter MS und langfristiger Sicherheitsdaten aus der EMPhASIS-Studie bei schubförmig-remittierender MS.
- None.
- None.
- September 8-10: H.C. Wainwright 27th Annual Global Investment Conference. Jason Tardio, President and Chief Operating Officer of Immunic, will present a company overview. The on-demand presentation will be available to view beginning Friday, September 5, 2025, at 7:00 am ET on the H.C. Wainwright Conference Portal and on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.
Mr. Tardio, Daniel Vitt, Ph.D., Chief Executive Officer and Jessica Breu, Vice President Investor Relations and Communications, will also participate in one-on-one investor meetings at the conference inNew York . To schedule a meeting, please log into www.hcwevents.com or contact Jessica Breu at: jessica.breu@imux.com. - September 17-19: 2025 Leerink Partners Biopharma Summit. Dr. Vitt will participate in this summit in
Healdsburg, CA. - September 24-26: 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Members of Immunic's management, medical, clinical and preclinical teams will attend this conference in
Barcelona, Spain . Data on Immunic's orally available lead-asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) will be presented in an oral presentation and four poster presentations, including one late-breaking poster. Additionally, the team will be available throughout the event at booth #B37. The presentation and all posters will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.
Oral Presentation:- Title: Efficacy and Safety of Vidofludimus Calcium, a Novel Nurr1 Activator and Selective DHODH Inhibitor, in Progressive Multiple Sclerosis: Data from the Phase 2 CALLIPER Trial
- Presenting Author: Robert J. Fox, M.D., Staff Neurologist, Mellon Center for Multiple Sclerosis, Vice-Chair for Research, Neurological Institute, Cleveland Clinic,
Cleveland, Ohio - Abstract Number: ECTRIMS25-1404
- Presentation ID: O024
- Session Title: Free Communications 2: Therapeutic interventions - from trials to real-world evidence
- Session Date: Wednesday, September 24, 2025
- Presenting Time: 2:35 pm – 2:45 pm CEST (8:35 am – 8:45 am ET)
- Location: Lecture Hall 117
Late Breaking Poster Presentation:
- Title: Efficacy and Safety of Vidofludimus Calcium, a Novel Nurr1 Activator and DHODH Inhibitor, in Primary Progressive Multiple Sclerosis (PPMS): Subpopulation Data from the Phase 2 CALLIPER Trial
- Abstract Number: IMS25-LBA-317
- Poster Number: P417
- Poster Session Title: Poster Session 1
- Session Date: Wednesday, September 24, 2025
- Session Time: 4:30-6:30 pm CEST (10:30 am - 12:30 pm ET)
Poster Presentations:
- Title: Potential Neuroprotective Activity by Vidofludimus Calcium in In Vivo Models of Multiple Sclerosis
- Abstract Number: ECTRIMS25-1142
- Poster Number: P167
- Poster Session Title: Poster Session 1
- Session Date: Wednesday, September 24, 2025
- Session Time: 4:30-6:30 pm CEST (10:30 am - 12:30 pm ET)
- Title: Update on the Assessment of Long-Term Safety and Tolerability of Vidofludimus Calcium in Patients with Relapsing-Remitting Multiple Sclerosis in the Open-Label Extension Period of the Phase 2 EMPhASIS Trial
- Abstract Number: ECTRIMS25-191
- Poster Number: P834
- Poster Session Title: Poster Session 2
- Session Date: Thursday, September 25, 2025
- Session Time: 4:30-6:30 pm CEST (10:30 am - 12:30 pm ET)
- Title: 144-Week Analysis of the Confirmed Disability Worsening Events in the Open-Label Treatment Extension of the Phase 2 EMPhASIS Study of Vidofludimus Calcium in Patients with Relapsing-Remitting Multiple Sclerosis
- Abstract Number: ECTRIMS25-1587
- Poster Number: P814
- Poster Session Title: Poster Session 2
- Session Date: Thursday, September 25, 2025
- Session Time: 4:30-6:30 pm CEST (10:30 am - 12:30 pm ET)
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor and scientific conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-investor-and-scientific-conferences-in-september-302543165.html
SOURCE Immunic, Inc.
FAQ
When and where will Immunic (IMUX) present at the H.C. Wainwright Conference in September 2025?
What clinical data will Immunic present at ECTRIMS 2025?
Who will be presenting Immunic's CALLIPER trial results at ECTRIMS 2025?
How can investors schedule meetings with Immunic management at the H.C. Wainwright Conference?
